Starjemza 130 mg/26mL
ustekinumab-hmny · INJECTION · Hikma Pharmaceuticals USA Inc.
No Recall History
Plain English
Starjemza is a injection containing ustekinumab-hmny at 130 mg/26mL, taken intravenous. Manufactured by Hikma Pharmaceuticals USA Inc..
Key Facts
- Brand Name
- Starjemza
- Generic Name
- ustekinumab-hmny
- NDC Code (Product)
0143-9171- Manufacturer
- Hikma Pharmaceuticals USA Inc.
- Strength
- 130 mg/26mL
- Dosage Form
- INJECTION
- Route
- INTRAVENOUS
- Marketing Status
- Application #
- BLA761419
- Drug Class
- Interleukin-12 Antagonist [EPC]; Interleukin-23 Antagonist [EPC]
- Marketing Start
- 10/27/2025
Recall History
No Recall HistoryFrequently Asked Questions
What is Starjemza used for?
Starjemza contains ustekinumab-hmny. It is a injection taken intravenous. Consult your doctor for specific uses.
Is Starjemza a controlled substance?
Starjemza is not classified as a controlled substance by the DEA.
What is the generic name for Starjemza?
The generic name for Starjemza is ustekinumab-hmny. There are no other listed brand versions of ustekinumab-hmny.
What is the NDC code for Starjemza 130 mg/26mL?
The NDC (National Drug Code) for Starjemza 130 mg/26mL is 0143-9171, listed by Hikma Pharmaceuticals USA Inc..
Other Starjemza Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)